2026 Cholesterol Guidelines: Normal Levels Explained by a GP

In March 2026, the American College of Cardiology and American Heart Association published their first major update to cholesterol management guidelines since 2018. It's a significant document — and while it's written for clinicians, the changes will directly affect how your cholesterol is assessed and treated, whether through the NHS or privately.

I've read the full guideline in detail. Here's what's actually changed, why it matters, and what you might want to discuss with your doctor.

Cholesterol Targets Are Back

The 2018 guidelines focused on reducing your LDL cholesterol by a certain percentage — typically 30–50% — without specifying an actual number to aim for. That approach worked in principle, but in practice it left a lot of patients and clinicians without a clear goal.

The 2026 guideline brings back specific LDL cholesterol targets, and they're tiered by how much cardiovascular risk you carry [Blumenthal et al., Circulation, 2026]:

• Borderline or intermediate risk (primary prevention): LDL-C below 2.6 mmol/L (100 mg/dL)

• High 10-year risk (≥10%, primary prevention): LDL-C below 1.8 mmol/L (70 mg/dL)

• Established cardiovascular disease (very high risk): LDL-C below 1.4 mmol/L (55 mg/dL)

The guideline also introduces non-HDL cholesterol targets alongside LDL-C targets, which gives a broader picture of your atherogenic risk — particularly useful if your triglycerides are raised.

What this means for you: if you're on a statin or considering one, there's now a clearer number to work towards. It makes monitoring more meaningful and gives you and your doctor a shared goal.

Everyone Should Have Their Lp(a) Checked — At Least Once

This is one of the most significant additions. Lipoprotein(a) — written Lp(a) and pronounced "lip-little-a" — is a type of cholesterol particle that's largely determined by your genetics. Unlike standard LDL cholesterol, it doesn't change much with diet or statins, and it's not routinely measured on a standard lipid profile.

The 2026 guideline now gives Lp(a) measurement a Class I recommendation (the strongest possible), stating that all adults should have it measured at least once for cardiovascular risk assessment [Blumenthal et al., Circulation, 2026]. Levels above 125 nmol/L (approximately 50 mg/dL) are associated with roughly a 1.4-fold increased risk of cardiovascular disease, and levels above 250 nmol/L (100 mg/dL) are associated with at least double the risk.

Why this matters: a significant proportion of the population — some studies suggest up to one in five people — have an elevated Lp(a), and most of them don't know it. Because it's genetically determined, it won't show up unless you specifically test for it. If your Lp(a) is high, the guideline recommends more intensive management of your other risk factors — particularly LDL cholesterol — to compensate.

A New Way of Calculating Your Risk

The old risk calculator (the Pooled Cohort Equations, or PCE) has been replaced with a newer model called the PREVENT equations. These are designed for adults aged 30 to 79 and can estimate both your 10-year and 30-year cardiovascular risk [Blumenthal et al., Circulation, 2026].

The risk categories have been redefined too. The new thresholds are: low (below 3%), borderline (3–<5%), intermediate (5–<10%), and high (10% or above). The guideline introduces a helpful mnemonic — "CPR": Calculate your 10-year risk, Personalise it with risk-enhancing factors not in the equation, and potentially Reclassify with a coronary artery calcium (CAC) scan if the decision about treatment is still uncertain.

The Case for Treating Cholesterol Earlier

One of the strongest themes in the new guideline is the emphasis on cumulative exposure. Cardiovascular disease doesn't begin the day you have a heart attack — it develops over decades as atherogenic lipoproteins gradually build up in your artery walls. The longer your LDL cholesterol has been elevated, the greater your lifetime risk.

The 2026 guideline now recommends considering statin therapy even in younger adults (aged 30 onwards) who are at low 10-year risk if their LDL cholesterol is between 4.1 and 4.9 mmol/L, or if their 30-year cardiovascular risk is 10% or above [Blumenthal et al., Circulation, 2026]. Previously, treatment in this group would have been unusual unless other risk factors were present.

This is a meaningful shift. It reflects growing evidence that treating earlier — even when short-term risk is low — reduces the total amount of damage done to arteries over a lifetime.

Coronary Artery Calcium Scoring Gets a Major Upgrade

Coronary artery calcium (CAC) scoring — a low-dose CT scan that measures calcified plaque in your coronary arteries — has been used for risk stratification for some time. But the 2026 guideline gives it a much more prominent and specific role.

CAC scores now directly determine LDL cholesterol targets [Blumenthal et al., Circulation, 2026]:

• CAC score of 0: reasonable to defer treatment and recheck in 3–7 years (unless other high-risk features are present)

• CAC 1–99 (below 75th percentile): moderate-intensity statin, targeting LDL-C below 2.6 mmol/L

• CAC 100–299 or ≥75th percentile: treatment to achieve LDL-C below 1.8 mmol/L

• CAC 300–999: LDL-C below 1.8 mmol/L, with consideration of intensifying to below 1.4 mmol/L

• CAC ≥1000: treated like established heart disease — LDL-C target below 1.4 mmol/L

Importantly, the guideline also says that if coronary calcium is spotted incidentally on a CT scan done for another reason — such as a lung screening CT — it should still be acted upon. This includes calcium detected by artificial intelligence algorithms, which is increasingly common.

ApoB: Looking Beyond the Standard Lipid Profile

Apolipoprotein B (ApoB) is a protein found on every atherogenic lipoprotein particle. Because each particle carries exactly one ApoB molecule, measuring it tells you the actual number of harmful particles in your blood — not just the amount of cholesterol they carry.

The 2026 guideline gives ApoB measurement a Class IIa recommendation (meaning "reasonable to do") as a way to refine your risk once LDL-C and non-HDL-C goals have been met [Blumenthal et al., Circulation, 2026]. It's particularly useful if you have elevated triglycerides (above 2.3 mmol/L), diabetes, or a low achieved LDL-C where the standard lipid panel may underestimate residual risk.

Dietary Supplements: Officially Not Recommended

The guideline is direct on this point. Fish oil supplements, garlic, turmeric, cinnamon, red yeast rice, and plant sterols are all given a Class III (No Benefit) recommendation for lowering LDL cholesterol or triglycerides [Blumenthal et al., Circulation, 2026]. The SPORT trial, which directly compared six commonly used supplements against low-dose rosuvastatin and placebo, found that none of the supplements significantly reduced LDL-C compared with placebo.

This doesn't mean supplements have no role in health generally — but for managing cholesterol specifically, the evidence isn't there. This is worth knowing if you're spending money on supplements in the hope of avoiding a statin.

New Recommendations for Specific Groups

The 2026 guideline adds explicit recommendations for several groups that were either absent or underserved in the 2018 version [Blumenthal et al., Circulation, 2026]:

• Chronic kidney disease (stage 3 or higher): statin therapy is now recommended regardless of LDL-C level in those aged 40–75, with high-intensity treatment for those with established cardiovascular disease

• People living with HIV: statin therapy is recommended for those aged 40–75 on stable antiretroviral therapy to reduce first cardiovascular events

• Cancer survivors: those with a life expectancy of at least two years who otherwise qualify for lipid-lowering therapy should be treated the same as the general population

• Reproductive risk markers: early menopause (before age 45) and adverse pregnancy outcomes such as pre-eclampsia and gestational diabetes are now formally recognised as risk-enhancing factors for cardiovascular disease

What Should You Do?

If you're already on a statin and your cholesterol is well managed, you probably don't need to change anything right away. But these guidelines do suggest some actions worth considering:

• Get your Lp(a) checked. It only needs to be measured once and it could reveal a risk that standard tests miss entirely. Most GP practices don't routinely test for it, but it's available through a private blood test.

• Know your targets. If you're on treatment, ask your doctor what LDL-C level you're aiming for. With clear goals now in place, monitoring becomes more meaningful.

• Don't rely on supplements for cholesterol management. The evidence is now definitive — they don't work for this purpose.

• If you're under 50 with raised cholesterol, take it seriously. The emphasis on cumulative exposure means earlier treatment can make a meaningful difference over decades.

How Brooksby Medical Can Help

At Brooksby Medical, we offer a comprehensive lipid profile that includes total cholesterol, LDL-C (calculated using the Martin-Hopkins equation, as recommended in the new guideline), HDL-C, non-HDL-C, and triglycerides. We also offer Lp(a) and ApoB testing — both highlighted as important additions in this guideline.

Every result comes with a doctor-written report by a GMC registered doctor. That means your numbers aren't just flagged as "normal" or "abnormal" — they're interpreted in the context of your overall risk, your history, and the latest evidence. It's the difference between getting a set of numbers and getting an explanation from a doctor who understands what they mean together.

Explore our cholesterol and heart health tests at brooksbymedical.com.

Written by Dr James Coleman, GP and founder of Brooksby Medical. Dr Coleman is a practising NHS General Practitioner who founded Brooksby Medical to give patients direct access to the blood tests and clinical interpretation they need, without waiting lists.

Medically reviewed: March 2026 | Next review due: March 2027

---

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Blood test results should always be interpreted by a qualified healthcare professional in the context of your individual symptoms, medical history, and clinical picture. If you have concerns about your health, please consult your GP.

Primary source: Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153. doi: 10.1161/CIR.0000000000001423

Order a private qFIT test

bowel cancer screening is another test worth considering alongside heart health checks

Learn More